Clinical Trials for Uterine Cancer

A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Enrolling adults with advanced solid tumors or lymphomas, including molecularly defined cohorts such as ARID1A-mutant endometrial/ovarian clear cell and other solid tumors, BAP1-loss mesothelioma, PTCL/DLBCL (including EZH2-mutant), and mCRPC. Investigational therapy is tulmimetostat (CPI-0209), an oral dual EZH2/EZH1 inhibitor, given as monotherapy across cohorts and combined with enzalutamide in mCRPC.

ClinicalTrials.gov ID: NCT04104776

A Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific Antibody) Administered in Combination With Other Agents in MUC16 + Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with MUC16-positive advanced ovarian, primary peritoneal/fallopian tube, or endometrial cancer after prior platinum (and prior anti–PD‑1 for endometrial) receive the investigational MUC16×CD28 costimulatory bispecific REGN5668 alone or combined with anti–PD‑1 cemiplimab, cemiplimab+anti–LAG‑3 fianlimab, or the MUC16×CD3 T‑cell engager ubamatamab (some cohorts with IL‑6R blocker sarilumab for CRS mitigation). Aims to enhance T‑cell activation against MUC16 tumors via CD28 costimulation with or without PD‑1/LAG‑3 blockade or CD3 engagement; key exclusions include prior MUC16‑targeted therapy, active autoimmune/CNS disease, and significant cardiac disease.

ClinicalTrials.gov ID: NCT04590326

Phase II Trial of Hypofractionated Radiochemotherapy for Women With Metastatic or Bulky Uterine Cervix Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Women with untreated FIGO 2018 stage IB3–IIIC1 bulky (≥6 cm) or limited-metastatic stage IVB cervical squamous/adenosquamous/adenocarcinoma (GOG PS 0–2) receive a condensed course of pelvic hypofractionated IMRT with two weekly doses of concurrent cisplatin radiosensitization (40 mg/m2) followed by HDR brachytherapy. The study assesses early MRI response, feasibility of timely completion, safety, and preliminary PFS/OS, with exploratory circulating tumor cell dynamics.

ClinicalTrials.gov ID: NCT06331468

An Open Label Phase II Study of the Efficacy and Safety of Abemaciclib, a Cyclin Dependent Kinase (CDK4/6) Inhibitor in Selected Patients With Recurrent Ovarian or Endometrial Cancer

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Biomarker-selected adults with recurrent ovarian (including fallopian tube/primary peritoneal) or endometrial cancer receive abemaciclib, a CDK4/6 inhibitor targeting cyclin D–CDK4/6–RB signaling; ovarian cases require CDK4/6 pathway activation, and endometrioid endometrial tumors must be HR-positive without CCNE amplification or RB loss. Hormone receptor–positive tumors may also receive an aromatase inhibitor (anastrozole or letrozole).

ClinicalTrials.gov ID: NCT04469764

A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced, measurable solid tumors (ECOG 0–1) eligible for biopsy, including FRα‑expressing cancers such as ovarian, receive the investigational FRα‑targeted topoisomerase‑I ADC AZD5335 (torvutatug samrotecan) as monotherapy or combined with bevacizumab, carboplatin (± bevacizumab), or PARP1‑selective inhibitors (saruparib or AZD9574). Aimed at patients who have exhausted standard options, with exclusions for uncontrolled CNS disease and significant comorbidities; early data suggest higher activity in FRα‑high tumors.

ClinicalTrials.gov ID: NCT05797168

A Phase Ib/II Single Arm Study of Cabozantinib Plus Dostarlimab in Women With Recurrent Gynecologic Carcinosarcoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolling adult women with recurrent gynecologic carcinosarcoma after at least one prior systemic regimen (ECOG 0–2), this single-arm study gives cabozantinib (oral MET/VEGFR2/AXL multikinase inhibitor) plus dostarlimab (anti–PD-1) with maintenance dosing. Key exclusions include prior cabozantinib, unstable CNS disease, significant bleeding/GI risk, uncontrolled CV/HTN, active autoimmune disease requiring systemic therapy, and contraindicated anticoagulation.

ClinicalTrials.gov ID: NCT05559879

A Phase 2 Multi-center Open-label Trial of Nab-Sirolimus in Combination With Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with advanced or recurrent endometrioid endometrial carcinoma (ECOG 0–1) with measurable disease and ≤1 prior systemic chemotherapy in the metastatic/advanced setting receive nab-sirolimus IV (albumin-bound mTORC1 inhibitor) on Days 1 and 8 of 21-day cycles plus daily letrozole. Excludes prior mTOR inhibitor exposure and active brain metastases; aims to assess response by RECIST with treatment continued until progression or intolerance.

ClinicalTrials.gov ID: NCT05997017

A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants With Advanced Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced/metastatic CLDN6-positive solid tumors (e.g., ovarian, endometrial, testicular, subsets of NSCLC) receive TORL-1-23 monotherapy, an anti-CLDN6 antibody–drug conjugate delivering MMAE via a cleavable linker, in dose-escalation with tumor-specific expansions. Eligible patients have ECOG 0–1 and adequate organ function; key exclusions include active/symptomatic CNS disease and uncontrolled comorbidities.

ClinicalTrials.gov ID: NCT05103683

Phase 2, Randomized, Trial of Maintenance Letrozole/Abemaciclib vs Pembrolizumab After Systemic Therapy in Patients With Advanced or Recurrent Estrogen Receptor Positive, Mismatch Repair Proficient, TP53 Wild-type Endometrial Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with ER-positive (≥1%), MMR-proficient, TP53 wild-type advanced or recurrent endometrioid endometrial cancer (or carcinosarcoma with endometrioid component) who have completed induction carboplatin/paclitaxel plus pembrolizumab are randomized to maintenance abemaciclib (CDK4/6 inhibitor) plus letrozole (aromatase inhibitor) versus pembrolizumab monotherapy. Designed to test whether endocrine/CDK4/6 maintenance improves PFS versus standard PD-1 blockade maintenance in this biomarker-defined, non–TMB-high population.

ClinicalTrials.gov ID: NCT06366347

A Phase 1/2 Study of REGN4018 (Ubamatamab), a MUC16×CD3 Bispecific Antibody, Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with recurrent epithelial ovarian, primary peritoneal, fallopian tube, or other MUC16-positive cancers (including MUC16+ endometrial) after prior platinum therapy and without standard options; a randomized cohort targets platinum‑resistant ovarian cancer after 2–4 prior lines. Investigational therapy is ubamatamab, a MUC16×CD3 T cell–engaging bispecific antibody, given IV as monotherapy or combined with the anti–PD‑1 antibody cemiplimab.

ClinicalTrials.gov ID: NCT03564340